| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | 568 | 9.797 | 18.564 | 33.510 | 26.708 | 36.312 | 39.663 | 50.833 |
| Total Income - EUR | - | - | 568 | 9.797 | 18.564 | 33.510 | 28.209 | 36.312 | 39.663 | 53.792 |
| Total Expenses - EUR | - | - | 7 | 4.050 | 6.793 | 8.342 | 15.906 | 15.848 | 33.345 | 31.328 |
| Gross Profit/Loss - EUR | - | - | 561 | 5.747 | 11.772 | 25.168 | 12.302 | 20.464 | 6.318 | 22.464 |
| Net Profit/Loss - EUR | - | - | 544 | 5.547 | 11.215 | 24.163 | 11.456 | 19.414 | 5.981 | 21.092 |
| Employees | - | - | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Neurosante Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | 0 | 0 | 0 | 1.882 | 2.689 | 46.182 | 42.140 | 45.671 |
| Current Assets | - | - | 605 | 6.124 | 17.428 | 38.028 | 47.976 | 3.737 | 5.589 | 5.491 |
| Inventories | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.693 |
| Receivables | - | - | 0 | 0 | -120 | 0 | 1.364 | 2.360 | 1.728 | 0 |
| Cash | - | - | 605 | 6.124 | 17.548 | 38.028 | 46.612 | 1.377 | 3.861 | 3.798 |
| Shareholders Funds | - | - | 544 | 6.124 | 17.220 | 39.652 | 50.229 | 19.828 | 25.748 | 46.697 |
| Social Capital | - | - | 0 | 43 | 42 | 41 | 40 | 406 | 404 | 402 |
| Debts | - | - | 61 | 0 | 208 | 257 | 436 | 30.091 | 21.981 | 4.466 |
| Income in Advance | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Neurosante Srl